[{"NetIncomeLoss_1_Q2_USD":-10426000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":17877988.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":17907393.0,"CommitmentsAndContingencies_0_Q2_USD":null,"LiabilitiesNoncurrent_0_Q2_USD":932000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":6941000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-1956000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":11884000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":37000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":149000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":3633000.0,"AssetsCurrent_0_Q2_USD":72076000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":19342000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":60000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":245000.0,"ForeignCurrencyTransactionGainLossRealized_2_Q2_USD":168000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":31261000.0,"CommonStockSharesIssued_0_Q2_shares":17915515.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":39700000.0,"Assets_0_Q2_USD":75448000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-74000.0,"MarketableSecuritiesRealizedGainLoss_2_Q2_USD":116000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-337000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":6912000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-164000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":20313000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":9148000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":1689000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":1335000.0,"ProceedsFromStockPlans_2_Q2_USD":106000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":5119000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":2186000.0,"CommonStockValue_0_Q2_USD":18000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":261000.0,"OperatingLeaseLiability_0_Q2_USD":1354000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":414000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":106000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-21315000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-10763000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":446000.0,"OtherAssetsNoncurrent_0_Q2_USD":178000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":16174000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":932000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":209750000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-169000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":-24000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":297000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1305000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2_Q2_USD":116000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":385000.0,"CommonStockSharesOutstanding_0_Q2_shares":17915515.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":220000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1248000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":211000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-127000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-11540000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":25192000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":390000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-142832000.0,"LiabilitiesCurrent_0_Q2_USD":9536000.0,"NonoperatingIncomeExpense_2_Q2_USD":5984000.0,"NonoperatingIncomeExpense_1_Q2_USD":2355000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":1517000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-65000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":1257000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":78000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":16174000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":1889000.0,"NetIncomeLoss_2_Q2_USD":-21241000.0,"AccountsPayableCurrent_0_Q2_USD":2173000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":39517000.0,"StockholdersEquity_0_Q2_USD":64980000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q2_USD":46000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":335000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":149000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-3031000.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"OperatingIncomeLoss_2_Q2_USD":-27225000.0,"OperatingIncomeLoss_1_Q2_USD":-12781000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":39700000.0,"InvestmentIncomeInterest_2_Q2_USD":451000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":35000.0,"InvestmentIncomeInterest_1_Q2_USD":193000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":2952000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":2436000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":137000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":422000.0,"OperatingExpenses_2_Q2_USD":27225000.0,"OperatingExpenses_1_Q2_USD":12781000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.19,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.58,"ProfitLoss_2_Q2_USD":-21241000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":75448000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":410000.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20201031","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201210"}]